Clinical Trial Update: Zanuburutinib in Relapsed and Refractory iMCD: a Prospective, Single-center, Single-arm Trial [Phase 2]

View source ↗

Summary

A Phase 2 prospective single-arm trial evaluating zanuburutinib for relapsed and refractory idiopathic multicentric Castleman's disease (iMCD).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Multicentric Castleman Disease

Drugs mentioned

• zanuburutinib (zanuburutinib)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Idiopathic Multicentric Castleman's Disease | Phase 2 | Status: UNKNOWN